Oxford BioTherapeutics is a clinical-stage oncology company, developing first-in-class antibody-based therapies to improve patient outcomes
Oxford BioTherapeutics is a clinical-stage oncology company, developing first-in-class antibody-based therapies to improve patient outcomes. Their proprietary, proteomic target discovery platform, OGAP®-Verify, specializes in identifying novel membrane-based protein targets.